Is Wegovy on the PBS in Australia? 2026 Status
Is Wegovy on the PBS in Australia? 2026 Listing Status, Criteria and Cost Guide
TL;DR
Wegovy is still not listed on the PBS in Australia. The Pharmaceutical Benefits Advisory Committee recommended listing for people with established cardiovascular disease and obesity back in November 2025, but the Department of Health rejected Novo Nordisk's pricing documentation in mid-2026, and formal listing arrangements have not commenced. Once listed, PBS patients would pay around $25 per script, or $7.70 with a concession card. Right now, Wegovy is only available on private prescription, at full out of pocket cost. This page tracks listing status and timeline only. For a full monthly pricing breakdown, see our Wegovy Australia Cost guide.
This article is general information only. It does not replace medical advice. Wegovy eligibility, including PBS eligibility once listing is confirmed, is assessed by a registered doctor.
Thousands of Australians search for Wegovy PBS listing information every week, and the volume of that search interest has grown noticeably over the past month as the negotiation between the government and Novo Nordisk has hit new complications. The short answer has not changed: Wegovy remains unavailable through the PBS. The PBAC recommendation was one necessary step toward listing, not the final approval, and the medicine is currently available only via private prescription while price negotiations continue.
HolisticChem is a Bayswater based compounding and telehealth pharmacy, and we track this listing process closely for the patients who ask us about it every day.
Is Wegovy on the PBS in Australia Right Now?
No, Wegovy is not yet listed on the PBS in Australia. The PBS medicine status page confirms the PBAC recommended semaglutide (Wegovy) for listing on 5 November 2025, but as of the government's most recent update (23 July 2026), the agreement to listing arrangements and the remaining government processes have both “not yet commenced.” Formal acceptance of Novo Nordisk's documentation has also not been granted.
What Happened With the Novo Nordisk Price Negotiations? [NEW SECTION]
The government rejected Novo Nordisk's pricing documentation. According to MedNews, the Department of Health, Disability and Ageing rejected Novo Nordisk's submitted pricing documents after months of negotiation, a setback first reported at the end of May 2026. Novo Nordisk maintains that talks are continuing. This matches the PBS medicine status page directly: the documentation lodged on 27 February 2026 is marked “Not Accepted,” and every stage after it, listing arrangements and final government sign-off, is still shown as not yet commenced.
This is the development behind the recent surge in people searching for Wegovy PBS negotiation news. It does not mean the listing has been cancelled. It means pricing talks between the government and the manufacturer have stalled and need to be revisited before the process can move to the next stage.
What Did the PBAC Recommend for Wegovy?
The Pharmaceutical Benefits Advisory Committee recommended semaglutide (Wegovy) for subsidised listing following its November 2025 meeting. The recommendation covers adults with established cardiovascular disease and obesity. Novo Nordisk opened a notice of intent on 20 February 2026 and lodged documentation on 27 February 2026, which the government has not accepted as complete.
Who Will Be Eligible for PBS Subsidised Wegovy?
Expected eligibility targets adults who have experienced a heart attack, stroke, or symptomatic peripheral arterial disease, combined with a body mass index of 35 or higher, or 32.5 or higher for people of Aboriginal, Torres Strait Islander, or Asian background. These criteria remain preliminary until formal confirmation. Health Minister Mark Butler and reports from Diabetes Australia and Diabetes Victoria support these thresholds, and a physician will make the final eligibility call once listing is confirmed.
This positions Wegovy as a medicine for obesity alongside existing cardiovascular disease, not as a general weight loss subsidy. People without a qualifying cardiovascular history will likely keep paying privately even after listing.
What Will Wegovy Cost Once It Is Listed on the PBS?
Eligible patients will pay the standard PBS patient contribution, capped at $25 per script for general patients or $7.70 for concession card holders. These are the current 2026 rates set by the Department of Health, Disability and Ageing and apply across all subsidised medicines. The general copayment dropped from $31.60 to $25.00 from 1 January 2026 under the government's cheaper medicines policy, with the concession rate locked until 2029.
There is a real cost to Australians in the meantime. As Health Minister Mark Butler put it in comments reported by newsGP, more than 400,000 Australians currently pay private prices just to access this class of weight loss medicine, “as much as $4,000 or $5,000 a year.”
How Much Does Wegovy Cost in Australia Right Now?
Without PBS subsidy, patients pay the full private price for Wegovy, which varies with the dose and the pharmacy. Lower starting doses during initial treatment typically run $180 to $290 a month. For the full monthly breakdown by dose, see our Wegovy Australia Cost guide. [DIFFERENTIATION LINK, NEW] Speak with a pharmacist about dose timing, or ask about alternatives such as Contrave while you wait for the PBS listing to progress.
When Will Wegovy Actually Be Listed on the PBS?
No confirmed listing date exists as of August 2026. Two stages remain incomplete on the government tracker: agreement on listing arrangements, and final government processes, neither with a published timeframe. Health Minister Mark Butler has publicly committed to finalising the listing and named the expected eligibility criteria, but a public commitment is not the same as a signed agreement. Price negotiations can run for months even after a positive PBAC recommendation, and this one has already stalled once. The most reliable way to track progress is the PBS medicine status page directly, not general news headlines.
Frequently Asked Questions
Is Wegovy the same medicine as Ozempic?
Both contain semaglutide, but they target different uses and doses. Ozempic treats type 2 diabetes and already appears on the PBS. Wegovy addresses weight management and is currently under PBS review for obesity with established cardiovascular disease.
Why have the Wegovy PBS negotiations stalled? [NEW FAQ]
The Department of Health rejected the pricing documentation Novo Nordisk submitted in February 2026, a setback reported in late May 2026. The PBAC recommendation itself has not changed. What has stalled is the price negotiation stage that has to be agreed before the listing can proceed to government sign off.
Will Wegovy be completely free under the PBS?
No. Even after listing, patients will pay standard PBS contributions, around $25 per script for general patients or $7.70 for concession card holders. The PBS substantially reduces the price but does not eliminate it.
What body mass index do you need to qualify for PBS subsidised Wegovy?
Current recommendations suggest 35 or higher, or 32.5 or higher for people of Aboriginal, Torres Strait Islander, or Asian background, combined with a history of heart attack, stroke, or symptomatic peripheral arterial disease. These thresholds remain unfinalised until listing is confirmed.
Can I get Wegovy on the PBS for weight loss alone, without heart disease?
The current recommendation limits listing to obesity with established cardiovascular disease, not weight loss on its own. People without a qualifying cardiovascular history will likely continue paying privately even after listing.
Where can I check the official status of the Wegovy PBS listing?
The PBS medicine status page tracks semaglutide's progress directly, including PBAC outcomes, documentation stages, and the final listing date once it happens. This is the most reliable source, ahead of general health news coverage.
Conclusion
Wegovy still does not have PBS approval in Australia, though the process has moved a long way since last year, and stalled once along the way. The PBAC has recommended listing, the expected eligibility criteria are public, and the remaining steps are price negotiation and government approval.
Three takeaways: check the PBS medicine status page for the latest official update rather than news headlines, budget for the full private price if you are starting Wegovy privately now, and talk to a doctor about whether your health history is likely to meet the expected cardiovascular disease and BMI criteria.
Our pharmacists are happy to answer your questions about the PBS process while you wait for a decision. Call our Bayswater pharmacy on 03 8204 6600.